ESPR / Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings

Esperion reported Q2 bempedoic acid revenue of $20.3M; we expect the bempedoic acid to surpass the 2023 consensus numbers. The ongoing Daiichi litigat more_horizontal

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares t more_horizontal

ANN ARBOR, Mich., July 18, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2023 financial results befo more_horizontal

Esperion (ESPR) reports mixed first-quarter 2023 results, wherein earnings miss and revenues beat estimates. The stock of the company surges 5% on Tue more_horizontal

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares t more_horizontal

Investors are attracted to penny stocks for their potential to provide exponential gains. It is very common to find such companies trading for fract more_horizontal

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. more_horizontal

An SEC filing by Esperion (ESPR) reveals that partner Daiichi Sankyo disagrees with the company's assessment that cardiovascular outcome CLEAR study d more_horizontal